-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] On August 15th, Kehua Biotech closed slightly up, up 92%, with a quotation of 101 yuan, a turnover of 135 million, and a turnover rate of 22.
The stock's share price has performed well recently, with 9 daily limits within 14 trading days, with a cumulative increase of over 45%, and a turnover rate of 352% during the perio.
On the news, Kehua Biotech recently issued an announcement stating that the company, Xi’an Tianlong Technology C.
, Lt.
and Suzhou Tianlong Biotechnology C.
, Lt.
submitted to the arbitral tribunal on August 3, 2022, respectively, “The Respondent’s Reconciliation Negotiations for All Parties.
Deadline" and "Applicant's Application for Suspension of the Trial of the Case", both parties will clearly submit the negotiation results before August 24.According to the "Civil Ruling", after review, the court held that the case of both parties complied with the statutory suspension of litigation, and ruled to suspend the litigation in this cas.
It is understood that in 2018, Kehua Biotech acquired 62% of Tianlong Technology for 550 million, and agreed to complete the acquisition of the remaining 38% of Tianlong Technology in 2021 at a stock price calculated according to Tianlong Technology's 2020 net profi.
.However, in 2020, the field of molecular diagnostics represented by PCR technology ushered in explosive growth, Tianlong Technology's performance has increased significantly, and its net profit has increased by 2355% over the previous yea.
Tianlong Technology proposed that the remaining 38% of the shares should be traded at 900 million as agreed in the contract or 25 times the profit of the current yea.
In 2021, Tianlong Technology initiated a lawsuit against Kehua Biology, requiring Kehua to continue to perform the contract, otherwise it will compensate 10% of the liquidated damage.
Due to the contract disputes between the two parties, the annual report of Kehua Biology could not be audited by S.
Now, after a lapse of one year, the negotiation between the two parties has finally made positive progress and is expected to reach a settlemen.
The industry believes that this will help the return of time option.
According to the data, Kehua Bio is an in vitro diagnostic company integrating R&D, production and sales, with rich production experience and a complete echelon of medical diagnostic product.
With R&D and innovation as the core driving force, the company has built two R&D technology platforms of clinical in vitro diagnostic reagents and automatic detection and analysis instrument.
Its self-produced products focus on four major sectors: immunodiagnosis, biochemical diagnosis, molecular diagnosis and point-of-care diagnosis (POCT.
It has more than 260 reagents and instrument products approved by the national drug regulatory authority, more than 80 domestic products that have passed the EU CE certification, and some products have also obtained certifications from the United States, South Korea and other countrie.
At the same time, the company's Italian subsidiary TGS independently owns more than 80 CE certified product.
Just recently, Kehua Bio has also successively received good news of obtaining multiple medical device registration certificates, including gastrin 17 (G-17) assay kits, which further boosted market confidenc.
Behind its achievements, it is inseparable from its strong R&D and innovation capabilitie.
Kehua Bio has set up a national post-doctoral research station (approved by the Ministry of Personnel), Shanghai Enterprise Technology Center, Shanghai Immunodiagnostic Reagent Engineering Technology Research Center and Shanghai In Vitro Diagnostic Reagent Technology Innovation Center,et.
At the same time, it attaches great importance to the integration of production, education and research, and successfully developed a high-sensitivity infectious disease screening technology platfor.
It will also join hands with Fudan University to deepen industry-university-research cooperation, build an enterprise innovation center with Fudan Guanghua Lingang, promote the technological integration of Kehua Biology and Fudan Lingang Industrialization Innovation Platform Biomedical Engineering Center, and jointly enhance the ability of technological innovation and industrial integratio.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyon.
The stock's share price has performed well recently, with 9 daily limits within 14 trading days, with a cumulative increase of over 45%, and a turnover rate of 352% during the perio.
On the news, Kehua Biotech recently issued an announcement stating that the company, Xi’an Tianlong Technology C.
, Lt.
and Suzhou Tianlong Biotechnology C.
, Lt.
submitted to the arbitral tribunal on August 3, 2022, respectively, “The Respondent’s Reconciliation Negotiations for All Parties.
Deadline" and "Applicant's Application for Suspension of the Trial of the Case", both parties will clearly submit the negotiation results before August 24.According to the "Civil Ruling", after review, the court held that the case of both parties complied with the statutory suspension of litigation, and ruled to suspend the litigation in this cas.
It is understood that in 2018, Kehua Biotech acquired 62% of Tianlong Technology for 550 million, and agreed to complete the acquisition of the remaining 38% of Tianlong Technology in 2021 at a stock price calculated according to Tianlong Technology's 2020 net profi.
.However, in 2020, the field of molecular diagnostics represented by PCR technology ushered in explosive growth, Tianlong Technology's performance has increased significantly, and its net profit has increased by 2355% over the previous yea.
Tianlong Technology proposed that the remaining 38% of the shares should be traded at 900 million as agreed in the contract or 25 times the profit of the current yea.
In 2021, Tianlong Technology initiated a lawsuit against Kehua Biology, requiring Kehua to continue to perform the contract, otherwise it will compensate 10% of the liquidated damage.
Due to the contract disputes between the two parties, the annual report of Kehua Biology could not be audited by S.
Now, after a lapse of one year, the negotiation between the two parties has finally made positive progress and is expected to reach a settlemen.
The industry believes that this will help the return of time option.
According to the data, Kehua Bio is an in vitro diagnostic company integrating R&D, production and sales, with rich production experience and a complete echelon of medical diagnostic product.
With R&D and innovation as the core driving force, the company has built two R&D technology platforms of clinical in vitro diagnostic reagents and automatic detection and analysis instrument.
Its self-produced products focus on four major sectors: immunodiagnosis, biochemical diagnosis, molecular diagnosis and point-of-care diagnosis (POCT.
It has more than 260 reagents and instrument products approved by the national drug regulatory authority, more than 80 domestic products that have passed the EU CE certification, and some products have also obtained certifications from the United States, South Korea and other countrie.
At the same time, the company's Italian subsidiary TGS independently owns more than 80 CE certified product.
Just recently, Kehua Bio has also successively received good news of obtaining multiple medical device registration certificates, including gastrin 17 (G-17) assay kits, which further boosted market confidenc.
Behind its achievements, it is inseparable from its strong R&D and innovation capabilitie.
Kehua Bio has set up a national post-doctoral research station (approved by the Ministry of Personnel), Shanghai Enterprise Technology Center, Shanghai Immunodiagnostic Reagent Engineering Technology Research Center and Shanghai In Vitro Diagnostic Reagent Technology Innovation Center,et.
At the same time, it attaches great importance to the integration of production, education and research, and successfully developed a high-sensitivity infectious disease screening technology platfor.
It will also join hands with Fudan University to deepen industry-university-research cooperation, build an enterprise innovation center with Fudan Guanghua Lingang, promote the technological integration of Kehua Biology and Fudan Lingang Industrialization Innovation Platform Biomedical Engineering Center, and jointly enhance the ability of technological innovation and industrial integratio.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyon.
